Healthcare use for acute gastrointestinal illness in two Inuit communities: Rigolet and Iqaluit, Canada by Harper, SL et al.
ORIGINAL RESEARCH ARTICLE
Healthcare use for acute gastrointestinal illness
in two Inuit communities: Rigolet and Iqaluit, Canada$
Sherilee L. Harper1*, Victoria L. Edge1,2, James Ford3, M. Kate Thomas1,4,
David Pearl1, Jamal Shirley5, IHACC6, RICG7 and Scott A. McEwen1
1Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada; 2Office of Public Health
Practice, Public Health Agency of Canada, Guelph, Ontario, Canada; 3Department of Geography, McGill
University, Montreal, Quebec, Canada; 4Centre for Food-borne, Environmental & Zoonotic Infectious
Diseases, Public Health Agency of Canada, Guelph, Ontario, Canada; 5Nunavut Research Institute, Iqaluit,
Nunavut, Canada; 6Indigenous Health Adaptation to Climate Change Research Group: Lea Berrang-Ford,
Cesar Carcamo, Alejandro Llanos, Shuaib Lwasa, Didacus Bambaiha Namanya; 7Rigolet Inuit Community
Government, Rigolet, Nunatsiavut, Labrador, Canada
Background. The incidence of self-reported acute gastrointestinal illness (AGI) in Rigolet, Nunatsiavut, and
Iqaluit, Nunavut, is higher than reported elsewhere in Canada; as such, understanding AGI-related
healthcare use is important for healthcare provision, public health practice and surveillance of AGI.
Objectives. This study described symptoms, severity and duration of self-reported AGI in the general population and
examined the incidence and factors associated with healthcare utilization for AGI in these 2 Inuit communities.
Design. Cross-sectional survey data were analysed using multivariable exact logistic regression to examine
factors associated with individuals’ self-reported healthcare and over-the-counter (OTC) medication utiliza-
tion related to AGI symptoms.
Results. In Rigolet, few AGI cases used healthcare services [4.8% (95% CI1.514.4%)]; in Iqaluit, some cases
used healthcare services [16.9% (95% CI11.224.7%)]. Missing traditional activities due to AGI (OR3.8;
95% CI1.1812.4) and taking OTC medication for AGI symptoms (OR3.8; 95% CI1.215.1) were
associated with increased odds of using healthcare services in Iqaluit. In both communities, AGI severity
and secondary symptoms (extreme tiredness, headache, muscle pains, chills) were significantly associated with
increased odds of taking OTC medication.
Conclusions. While rates of self-reported AGI were higher in Inuit communities compared to non-Inuit communities
in Canada, there were lower rates of AGI-related healthcare use in Inuit communities compared to other regions in
Canada. As such, the rates of healthcare use for a given disease can differ between Inuit and non-Inuit communities,
and caution should be exercised in making comparisons between Inuit and non-Inuit health outcomes based solely
on clinic records and healthcare use.
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lobally, there are substantial disparities in health
outcomes between Indigenous and non-Indigenous
peoples; these disparities span most indicators
of health and wellbeing (1). Contributing to poor health
outcomes is the often lower healthcare use and access
among a number of Indigenous populations globally (2). A
Canadian study comparing Indigenous to non-Indigenous
populations found many indicators of use, access and
quality of healthcare services to be significantly worse
for Indigenous populations, including significantly lower
numbers visiting a physician, perceived lower healthcare
service accessibility and significantly higher reported un-
met healthcare needs for Indigenous people (3). To address
these inequities in healthcare, it is important to better
understand healthcare use and health practices specific to
Indigenous populations to help inform and further develop
$This research is part of an international project entitled the ‘‘Indigenous Health Adaptation to Climate Change’’ project, with parallel field study sites in Uganda
and Peru.
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appropriate primary and public healthcare that will en-
hance accessibility and quality of care and reflect demand.
In the case of acute gastrointestinal illness (AGI), health-
care use research has informed public health surveillance
and medical services at national and provincial levels
(47). AGI includes diarrhoea and/or vomiting caused by
a variety of conditions that cause acute gastrointestinal
symptoms, including infections with pathogens transmit-
ted by person-to-person contact or contaminated food
or water. For a case of AGI to be captured by a national
surveillance system, the case has to come in contact with
the healthcare system. For instance, in Canada, the case
must visit a healthcare provider, the healthcare provider
must request a stool sample, the case must comply and
submit a stool sample for testing, the sample must be
tested, the sample must test positive for a pathogen that
is deemed reportable, and positive cases must be reported
to provincial and national health authorities (8). Any break
in this chain of events will result in the case not being
captured by surveillance efforts; as such, cases of AGI are
under-ascertained by surveillance systems due to under-
diagnosis and under-reporting (4,5,810). The under-
ascertainment of infectious AGI cases in surveillance
systems has important implications for program planning,
resource prioritization, and outbreak detection and man-
agement (4,5,810). Therefore, several studies have been
conducted within communities to estimate the incidence of
AGI in the general population compared to the incidence
rates captured by surveillance systems, which allows health
authorities to account for under-ascertainment and adjust
interpretations of AGI surveillance data (4,5,810).
The decision to treat AGI symptoms at home and/or
seek healthcare depends on a number of factors, including
severity of illness, primary and secondary symptoms ex-
perienced, demographic characteristics, engagement with
and perceptions of healthcare and illness, among others
(5,9). It is important to understand what factors are
associated with AGI healthcare use, as well as the
similarities and differences between the types of cases
captured by health systems compared to those cases who
are not captured by health systems. This improves our
understanding of what makes someone more or less likely
to be counted in reportable disease statistics (4,5,810); in
other words, who is counted and why. This information is
valuable to inform and improve medical service provision
and adjust for biases in surveillance data that are used for
public health planning, programming, monitoring and
practice. This research is typically conducted at the
national or city level, and generally has not extended to
subpopulations experiencing disparities in health out-
comes, including Indigenous peoples.
In Canada, when using data from clinic records and
surveillance systems there seems to be little difference be-
tween laboratory-confirmed AGI rates in northern Indi-
genous communities compared to non-Indigenous southern
communities (1113); however, when using data from
surveys of the general population, self-reported AGI (not
necessarily laboratory confirmed) was much higher in
2 northern Indigenous communities compared to similar
studies in non-Indigenous communities in Canada and
abroad (14) (Fig. 1). This difference suggests that Indi-
genous communities might interact with the healthcare
system differently than other non-Indigenous communi-
ties for AGI symptoms. The contradiction between the
relatively low incidence of AGI cases identified by sur-
veillance systems and the relatively high incidence of
Fig. 1. The estimated annual incidence of acute gastrointestinal illness (case definition: 3 or more loose stools/day and/or vomiting in the
past 28 days) for Malta (20), Argentina (21), Quebec (22), Poland (23), China (24), Australia (25), Netherlands (7), Chile (26), Italy (6),
Nunavik (27), Cuba (28), Denmark (29), Rigolet (14) and Iqaluit (14).
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self-reported AGI in Inuit communities has implications
for AGI-related primary healthcare and public health
practice, as well as decisions that are based on national
surveillance data. Therefore, this study examined self-
reported medication and healthcare use related to AGI in
2 Inuit communities. Specifically, this study used cross-
sectional community surveys to (a) describe symptoms,
severity and duration of self-reported AGI, (b) examine
and compare the proportion of cases consulting with health-
care professionals with the proportion of stool samples
requested and submitted (e.g. the level of AGI under-
diagnosis) and (c) identify factors associated with medica-
tion and healthcare use for AGI symptoms in 2 Inuit
communities: Rigolet, Nunatsiavut, and Iqaluit, Nunavut.
Methods
Study locations
This study was part of a larger study that found high
incidence rates of AGI in Iqaluit, Nunavut, and Rigolet,
Nunatsiavut, Labrador, compared to other regions in
Canada (14,15). We partnered with these 2 communities
based on prior research relationships and community-
identified research interests. By working with 2 commu-
nities, we attempted to capture information from a small
and large Inuit settlement, urban and remote setting, and
from 2 Inuit regions. Iqaluit is the capital city of Nunavut
(Fig. 2) and has 6,699 residents, primarily Indigenous
people (62%) (16). In Iqaluit, the Qikiqtani General
Hospital and the Public Health Centre are staffed with
physicians and nurses. Patients requiring more specialized
services are flown south for treatment. Healthcare servi-
ces are paid by the Government of Nunavut’s Nunavut
Health Care Plan for all residents, and the services not
covered by the Territorial Plan are paid by the Non-
insured Health Benefits (NIHB) Program for Inuit
beneficiaries, which is paid by the Federal Government
and administered by the Territory. The Extended Health
Benefits Program provides coverage for non-Inuit resi-
dents. The Government of Nunavut and Federal Govern-
ment also provide broad health coverage (e.g. Great West
Life) to their employees in all Nunavut communities.
Rigolet is a small Inuit community located on the north-
east coast of Labrador in the province of Newfoundland
and Labrador (Fig. 2), with approximately 269 residents,
94% of whom identify as Indigenous (16). The commu-
nity’s health clinic has 2 resident nurses and a visiting
physician (every 6 weeks). When necessary, patients are
Fig. 2. A map displaying the 2 partner study communities: Rigolet, Nunatsiavut, and Iqaluit, Nunavut, Canada.
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medically evacuated by air to the Labrador Health
Center in Goose Bay, Labrador. Medical services are
paid for by the Province of Newfoundland and Labra-
dor’s Medical Care Plan, as well as the NIHB Program
for Inuit beneficiaries which is paid by the Federal
Government and administered by the Nunatsiavut Gov-
ernment. In both Iqaluit and Rigolet, the NIHB Program
pays for a range of prescription and over-the-counter
(OTC) medications for Inuit residents if a prescription
from a licensed practitioner is obtained.
Data collection
Data were collected as part of a larger burden of AGI
study (14). Two cross-sectional surveys were conducted in
both Rigolet and Iqaluit: one survey in September 2012
and one survey in May 2013 in an attempt to capture
seasonality of AGI outcomes, risk factors and healthcare
use. The case definition that was used for AGI included
self-reported vomiting and/or diarrhoea in the past 14 days
(September and May surveys) and in the past 28 days
(May survey only) (4,10). In an attempt to capture inci-
dent cases, if the date of AGI symptom onset was prior
to the 14-day/28-day recall period, the case was excluded.
Cases were excluded if the participant believed that their
recent AGI symptoms were due to pregnancy, medication
use, alcohol/drug use, or diagnosed chronic conditions
(e.g. colitis, diverticulitis, Crohn’s disease, irritable bowel
syndrome, current H. pylori, or other diagnosed chronic
conditions). Cases were defined as mild (less than 3 loose
stools and/or a single episode of vomiting in 1 day or less),
moderate (3 or more loose stools and/or 2 or more episodes
of vomiting, lasting for less than 1 day) and severe (3 or
more loose stools and/or 2 or more episodes of vomiting,
lasting for more than 1 day) (17). The case definitions, as
well as the mild, moderate and severe classifications, were
selected to facilitate comparisons with national and inter-
national studies examining the self-reported burden of AGI
using similar case definitions and methods (4,10,17).
The following data were also gathered: primary and
secondary symptoms; consulting a nurse or physician;
prescription and OTC medication use; traditional Inuit
medication use (e.g. local herbs and teas); traditional
Inuit healing practices (e.g. use of country foods); impact
of AGI on productivity including missed employment,
school and traditional activities (e.g. hunting, fishing,
trapping, visiting cabins, carving, crafts and so on); socio-
economic indicators [e.g. over-crowding, food security
status (18)]; and demographic information (14).
In Rigolet, a census sample was attempted; every
individual in every household who was in the community
during the study period was invited to participate. In
Iqaluit, a target sample size of 498 randomly selected
participants for each survey was calculated using a 2%
allowable error and a 95% confidence level to detect an
expected prevalence of 6% based on a population of
6,184 people (14). To randomly select participants, first
houses were randomly selected using a City of Iqaluit
Housing Atlas, with at least 2 in-person attempts per
house at different times of the day (during the day, and
then during weekends or evenings) on different days of
the week. Following successful contact, an individual
from the household was randomly selected using the last
birthday method and invited to participate in the survey.
All ages were eligible to participate, and for participants
under 12, the parent could act as a proxy respondent. A
research licence was obtained from the Nunavut Research
Institute, and the study protocol was approved by the re-
search ethics boards at the University of Guelph, McGill
University and Health Canada, and the Nunatsiavut
Government Research Advisory Committee.
Data analysis
Only data from individuals fitting the AGI case definition
were included in the analyses. Participants responding
‘‘unsure’’ or ‘‘refused to answer’’ were excluded from the
analysis of that question. In both communities, there was
no significant difference in medication or healthcare use
outcomes between September and May surveys (pB0.05).
Considering the small number of cases and the lack
of statistical difference between surveys, data from the
September and May surveys were combined for analyses.
Descriptive statistics were used to examine the symptoms,
severity and duration of self-reported AGI (objective 1).
The level of under-diagnosis was explored by descrip-
tively comparing the proportions of self-reported cases,
cases who reported to visit a healthcare professional, and
cases who reported to submit a stool sample (objective 2).
To identify factors potentially associated with health-
care use for AGI symptoms (objective 3), in Rigolet, a
series of univariable exact logistic regression models were
built to examine unconditional associations between
potential risk factor variables and OTC medication use.
In Iqaluit, 2 multivariable exact logistic models were built
with the following outcome variables: (a) visiting a health
clinic or hospital and (b) taking OTC medications for AGI.
First, a causal diagram was built to explore and identify
potential risk factors of interest based on peer-reviewed
literature and biological plausibility. Then, a series of
univariable exact logistic regression models were built with
risk factor variables of interest (significance levels based on
the conditional scores test) (19). Those predictor variables
with pB0.20 in the univariable models were considered in
the multivariable model using an iterative manual forward-
step model building approach. Predictors remained in the
model if significant (aB0.05) or if they were identified as a
confounder (e.g. inclusion resulted in more than a 30%
change in the b-coefficient) (19). To avoid collinearity
issues, the correlation between predictors variables was
assessed using Spearman rank correlation analysis, using a
cut-point value of 70%. If the correlation was above 70%,
Sherilee L. Harper et al.
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Table I. Treatment, duration and severity of acute gastrointestinal illness in Rigolet, Nunatsiavut, in September 2012 and May 2013
Rigolet
September and May combined
Treatment, duration and severity
All cases
% (95% CI)
Mean [range]
Mild cases
% (95% CI)
Mean [range]
Moderate cases
% (95% CI)
Mean [range]
Severe cases
% (95% CI)
Mean [range]
Age
019 24.2% (14.936.7%) 37.5% (19.859.4%) 64.3% (34.086.3%) 25.0% (11.047.4%)
2055 56.5% (43.668.5%) 50.0% (29.770.3%) 35.7% (13.766.0%) 58.3% (36.977.1%)
Over 55 19.4% (11.231.5%) 12.5% (3.734.5%) 0% 16.7% (5.938.9%)
Sex
Male 43.5% (31.556.4%) 33.3% (16.755.5%) 42.9% (18.371.6%) 54.2% (33.273.7%)
Female 56.5% (43.668.5%) 66.7% (44.583.3%) 57.1% (28.481.7%) 45.8% (26.366.8%)
Indigenous identity
Non-Indigenous person 3.2% (0.812.4%) 8.3% (1.930.2%) 0% 0%
Indigenous person 96.8% (87.699.2%) 91.7% (69.898.1%) 100% 100%
Treatment
Over-the-counter medications 32.3% (21.645.2%) 16.7% (5.938.9%) 50.0% (23.276.8%) 37.5% (19.859.4%)
Prescribed medications 1.6% (0.211.1%) 0% 7.1% (0.744.1%) 0%
Traditional medications 0% 0% 0% 0%
Visited clinic or hospital 4.8% (1.514.4%) 0% 7.1% (0.744.1%) 8.3% (1.930.2%)
Severity
Mean number of diarrhoea on worst day 2.94 [16] 1.38 [12] 4.00 [116] 3.81 [16]
Mean number of times vomiting on worst day 2.15 [16] 1.00 [11] 3.00 [24] 2.38 [16]
Duration of illness
Mean duration of AGI illness (days) 2.30 [17] 1.00 [11] 1.00 [11] 3.17 [27]
Mean duration of diarrhoea symptoms (days) 1.63 [17] 1.00 [11] 1.00 [11] 2.89 [27]
Mean duration of vomiting symptoms (days) 1.8 [17] 1.00 [11] 1.00 [11] 2.33 [17]
Missed activities
Mean duration of missed usual activities (days) 0.33 [04] 0.04 [01] 0.21 [01] 0.67 [04]
Mean duration of missed work (days) 0.21 [04] 0.21 [02] 0.21 [01] 0.21 [04]
Mean duration of missed traditional activities (days) 0.16 [03] 0.04 [01] 0.00 [00] 0.38 [03]
Mean duration of missed work for caregiver (days) 0.16 [01] 0.04 [01] 0.00 [00] 0.00 [00]
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Table II. Treatment, duration and severity of acute gastrointestinal illness in Iqaluit, Nunavut, in September 2012 and May 2013
Iqaluit
September and May combined
Treatment, duration and severity
All cases
% (95% CI)
Mean [range]
Mild cases
% (95% CI)
Mean [range]
Moderate cases
% (95% CI)
Mean [range]
Severe cases
% (95% CI)
Mean [range]
Age
019 18.4% (12.526.3%) 16.7% (4.844.1%) 14.0% (6.228.5%) 21.9% (13.234.0%)
2055 63.2% (54.371.3%) 55.6% (30.977.8%) 72.1% (56.383.8%) 59.4% (46.770.9%)
Over 55 18.4% (12.526.3%) 27.8% (10.954.7%) 14.0% (6.228.5%) 18.8% (10.830.5%)
Sex
Male 36.0% (28.044.9%) 55.6% (30.977.8%) 32.6% (19.948.4%) 32.8% (22.245.5%)
Female 64.0% (55.172.0%) 44.4% (22.269.1%) 67.4% (51.680.1%) 67.2% (54.577.8%)
Indigenous identity
Non-Indigenous person 32.3% (24.541.1%) 38.9% (18.264.5%) 40.5% (26.356.4%) 25.0% (15.737.4%)
Indigenous person 67.7% (58.975.5%) 61.1% (35.581.8%) 59.5% (43.673.7%) 75.0% (62.684.3%)
Treatment
Over-the-counter medications 45.6% (37.054.5%) 27.8% (10.954.7%) 34.9% (21.850.7%) 57.8% (45.169.5%)
Prescribed medications 8.8% (4.915.3%) 5.6% (0.635.5%) 9.3% (3.423.1%) 9.4% (4.219.7%)
Traditional medications 10.4% (6.117.2%) 11.1% (2.438.9%) 9.3% (3.423.1%) 10.9% (5.221.6%)
Visited clinic or hospital 16.9% (11.224.7%) 5.9% (0.737.3%) 16.3% (7.731.1%) 20.3% (12.032.3%)
Severity
Mean number of diarrhoea on worst day 3.80 [16] 1.54 [12] 4.17 [26] 4.13 [16]
Mean number of times vomiting on worst day 3.16 [16] 1.00 [11] 3.4 [16] 3.37 [16]
Duration of illness
Mean duration of AGI illness (days) 3.17 [17] 1.00 [11] 1.00 [11] 3.83 [27]
Mean duration of diarrhoea symptoms (days) 2.34 [17] 1.00 [11] 1.00 [11] 3.35 [27]
Mean duration of vomiting symptoms (days) 1.91 [17] 1.00 [11] 1.00 [11] 2.67 [17]
Missed activities
Mean duration of missed usual activities (days) 1.01 [07] 0.21 [02] 0.88 [04] 1.29 [07]
Mean duration of missed work (days) 0.83 [07] 0.40 [03] 0.69 [04] 1.03 [07]
Mean duration of missed traditional activities (days) 0.75 [07] 0.12 [02] 0.51 [07] 1.08 [07]
Mean duration of missed work for caregiver (days) 0.31 [07] 0.17 [02] 0.23 [03] 0.41 [07]
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the most biologically plausible variable was used in the
model building process (19). All analyses were conducted
using Stata IC (version 11.2).
Results
In Rigolet a census was attempted: of the 245 people in
the community during the September 2012 survey period,
a total of 226 people agreed to participate in the survey
(92% response rate); of the 249 people in the community
during the May 2013 survey, a total of 236 people agreed
to participate in the survey (95% response rate). In Iqaluit,
532 (September) and 520 (May) randomly selected parti-
cipants from randomly selected households completed
the questionnaire, yielding response rates of 75 and 55%,
respectively. There were 62 participants in Rigolet and
125 participants in Iqaluit who reported AGI symptoms
that fit the case definition (Tables I and II). Only these
AGI cases were considered in the analysis.
AGI symptoms and severity
In both communities, most cases were classified as severe
(38.7% in Rigolet; 51.2% in Iqaluit), followed by moderate,
and mild AGI; cases seeking treatment were most often
in the severe category (Tables I and II). In Iqaluit, severe
symptoms were reported by more women (67.2% of total
severe cases) than men, and by more Indigenous people
(75.0% of total severe cases) than non-Indigenous people
(Tables I and II). The treatment, duration, producti-
vity impacts and demographics of cases are stratified by
severity of illness in Table I and II. Primary and secon-
dary AGI symptoms are stratified by severity and presen-
ted in Fig. 3.
AGI and OTC medication use
In Rigolet, approximately one-third of cases took OTC
medications (Tables I and II). Univariable exact logistic re-
gression analysis found increased odds of OTC medication
Fig. 3. An overview of acute gastrointestinal illness case counts of primary symptoms, secondary symptoms, and reasons for not
seeking healthcare by severity for Rigolet, Nunatsiavut (a), and Iqaluit, Nunavut (b), in September 2012 and May 2013.
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use was unconditionally associated with secondary
symptoms (headache, extreme tiredness, chills and muscle
pain), as well as lower education levels of the household
head (Table III). In Iqaluit, many cases reported taking
OTC medications for their illness and few cases reported
taking traditional medicines (Tables I and II). In Iqaluit,
the final multivariable exact logistic regression model
found increased odds of taking OTC medication were
associated with missing paid employment due to illness
and severe AGI symptoms (Table IV).
Healthcare use
In Rigolet, it was rare for cases to visit the health clinic
for their illness, and of the 3 cases who visited the clinic,
none were asked to submit stool samples (Tables I and II;
Figs. 4 and 5). Therefore, statistical analyses to identify
potential predictors of healthcare use in Rigolet were
precluded. In Iqaluit, some cases went to the hospital for
treatment of AGI (Tables I and II; Figs. 4 and 5). Of
the 21 cases who visited a clinic in Iqaluit, 7 (33.3%) were
asked to submit a stool sample and 5 complied (71.4%)
(Figs. 4 and 5). In Iqaluit, the odds of visiting the clinic
or hospital for AGI was associated with missing tradi-
tional activities due to AGI symptoms, as well as taking
OTC medication for AGI (Table V). The odds of a health-
care provider requesting a stool sample was higher for
Indigenous cases than non-Indigenous cases, when con-
trolling for diarrheal symptoms (OR8.4; n21; 95%
CI1.187.6; p0.03).
Discussion
This cross-sectional survey facilitated the characteri-
zation of self-reported AGI symptoms and severity, and
an examination of AGI factors associated with OTC
medication use and healthcare use in 2 Inuit communities.
Despite the higher self-reported incidence of AGI pre-
viously reported in Rigolet and Iqaluit (14) (Fig. 1), this
study found lower levels of healthcare and OTC medica-
tion use for AGI symptoms compared to other areas
in Canada (4) and abroad (6,20,21,23,24,28) (Fig. 4).
Healthcare use rates for AGI in Rigolet were among the
lowest reported rates in the literature (6,20,21,23,24,28);
however, in Iqaluit, the proportion of cases visiting
healthcare providers was lower than some studies
(6,20,21,23,24,28), but higher than others (7,22,26,29).
The trend of lower healthcare use for AGI symptoms
was similar to that reported for other health outcomes in
Indigenous communities in Canada and abroad, which
found significantly lower healthcare access and use rates
in Indigenous populations compared to non-Indigenous
communities in the same country (2,30). Furthermore, a
study in British Columbia Canada found lower levels of
healthcare use for AGI in rural regions than semi-urban
and urban regions (4). There are unique factors that
influence healthcare use and demand in Indigenous and
rural communities, including the social and financial costs
of leaving the community for specialized services, cultural
differences, language barriers, racism and difficulties
Table III. Univariable exact logistic regression, examining the effects of predictor variables on the odds of taking over-the-counter
(OTC) medication for AGI in Rigolet, Nunatsiavut (September 2012 and May 2013)
Rigolet OTC medication use (September and May)
Univariable exact logistic
results
Predictor variable n Odds ratio p* 95% CI
No. of secondary symptoms reported None 36 ref.
1 9 4.946 0.043 0.83032.521
2 17 3.581 0.053 0.86915.560
Education level of household head High school or less 41 ref.
Post-secondary 20 0.254 0.046 0.0411.088
Extreme tiredness No 41 ref.
Yes 19 4.740 0.009 1.30218.583
Headache No 41 ref.
Yes 18 11.910 0.001 2.89858.550
Muscle pains No 45 ref.
Yes 13 4.273 0.026 1.00520.226
Chills No 45 ref.
Yes 13 6.680 0.005 1.50935.916
*Score method for estimating p-values does not assume a symmetrical distribution for discrete data. pB0.05 was considered significant.
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Table IV. Univariable exact logistic regression (for variables with pB0.20) and final multivariable logistic regression results, examining the effects of predictor variables on the odds of
taking over-the-counter (OTC) medication for AGI in Iqaluit, Nunavut (September 2012 and May 2013)
Iqaluit OTC medication use (September and May)
Univariable exact logistic results Final multivariable exact logistic results
Predictor variable n Odds Ratio p* 95% CI Odds Ratio p* 95% CI
Variables in the final multivariable model
Missed paid employment due to AGI No 71 ref. ref.
Yes 51 5.024 B0.001 2.19011.986 5.649 B0.001 2.35714.417
Severity of illness Mild cases 18 0.285 0.777 0.0710.980 0.216 0.041 0.0571.022
Moderate cases 43 0.394 0.033 0.1620.933 0.344 0.019 0.1240.902
Severe Cases 64 ref. ref.
Variables considered in building the multivariable model
Chill No 72 ref.   
Yes 52 3.658 0.001 1.6398.411   
Extreme thirst No 67 ref.   
Yes 55 2.004 0.069 0.9174.441   
Fever (self-reported) No 77 ref.   
Yes 47 2.421 0.026 1.0895.492   
Headache No 64 ref.   
Yes 57 1.842 0.103 0.8434.079   
Muscle pains No 79 ref.   
Yes 41 1.967 0.086 0.8604.568   
Nausea No 55 ref.   
Yes 67 2.370 0.028 1.0715.369   
Stomach cramps No 31 ref.   
Yes 91 1.955 0.145 0.7775.201   
Vomited No 70 ref.   
Yes 55 2.850 0.006 1.3026.379   
Missed daily activities due to AGI No 58 ref.   
Yes 62 0.517 0.098 0.2321.133   
Missed traditional activities due to AGI No 95 ref.   
Yes 28 2.302 0.083 0.9026.094   
Age 019 23 ref.   
2055 79 0.330 0.031 0.1070.947   
Over 55 23 0.589 0.550 0.1502.216   
*Score method for estimating p-values does not assume a symmetrical distribution for discrete data. pB0.05 was considered significant.
H
e
a
lth
c
a
re
u
tiliza
tio
n
in
R
ig
o
le
t
a
n
d
Iq
a
lu
it
C
ita
tio
n
:
In
t
J
C
irc
u
m
p
o
la
r
H
e
a
lth
2
0
1
5
,
7
4
:
2
6
2
9
0
-
h
ttp
://d
x.d
o
i.o
rg
/1
0
.3
4
0
2
/ijc
h
.v7
4
.2
6
2
9
0
9
(p
a
g
e
n
u
m
b
e
r
n
o
t
fo
r
c
ita
tio
n
p
u
rp
o
s
e
)
associated with travel (2,13,30,31). Another potential
barrier to AGI healthcare use in Iqaluit among Inuit,
might be the fear of long wait times at the hospital. When
community health centers experience staffing shortages,
wait times can be long for individuals with illnesses not
perceived to be ‘‘serious’’ or ‘‘urgent’’. During such times,
people are occasionally advised to wait until the next
available clinic if their symptoms are minor (32). Some
individuals may also fear contracting a new hospital
acquired infection, or spreading their AGI infection to
others during prolonged stays in crowded hospital wait
rooms. In addition to experiencing linguistic barriers
(absence of an interpreter) that may disable communica-
tion of their condition, Inuit have questioned the thor-
oughness and effectiveness of the diagnosis and treatment
received from health care professionals (32). Perceptions
of the quality and responsiveness of local healthcare services
may influence whether Inuit in Iqaluit decide to seek medical
attention for an AGI-related condition. Inuit sometimes
consult Elder family members for advice on how best to treat
children with stomach illnesses (32). This advice may be
another factor in determining whether parents seek medi-
cal attention or decide to self manage AGI symptoms in
children. These factors may have contributed to lower AGI-
related healthcare use in this study, which warrants further
investigation to continue improving the accessibility and
suitability of healthcare provision in the north.
Unlike other studies in Canada (4) and USA (5), the
severity of symptoms was not associated with health-
care use in Iqaluit; however, missing paid employment
and traditional activities were associated with increased
healthcare use. This finding reflects pervious research that
suggested some Inuit do not characterize AGI severity by
physiological symptoms (i.e. Acute Clinical Model of
Health), but rather in terms of lost productivity (i.e. Role
Performance Model of Health) (15,33). The goal of seek-
ing healthcare treatment in the Acute Clinical Model is to
reduce and relieve symptoms, which is common in urban,
Western settings. Whereas, the goal of seeking healthcare
treatment in the Role Performance Model is to increase
functional ability to fulfil work, family and community
roles and responsibilities, which is more common in
rural and Indigenous contexts (15,33). These differences
in how severity of AGI is defined and the goal of seeking
healthcare might help explain why severity of AGI
symptoms were associated with healthcare use in other
studies but not in Iqaluit, as well as why lost productivity
was associated with healthcare use in Iqaluit, but not
in other studies. It is also important to note that in
Iqaluit, many employers require a note from a healthcare
provider if an individual misses more than 3 days of work.
Furthermore, taking OTC medication was also associated
with healthcare use, which is similar to results in Canada
(4) and could suggest that cases attempted to self-treat
AGI before they decided to interact with the healthcare
system. Alternatively, it could suggest that the case took
OTC medication after the clinic visit at the recommenda-
tion of a healthcare provider. Unlike past studies, age and
sex were not associated with healthcare use (5). Taken
together, our results could suggest that factors associated
with healthcare use in the North are different than the
South, which could result in differential biases in types of
cases captured in national surveillance system data. That
is, in the South, studies suggest that children, elderly and
cases with severe symptoms are over-represented in clinic
and hospital AGI data (4,5); in the North, our results
suggest that cases with lost productivity are more likely
to use healthcare services and are thus over-represented
in clinic or hospital records. This difference should be
considered when using clinic records, hospital records, or
surveillance data in examining and comparing the burden
of AGI in the North to other locales.
The use of OTC medications within a community varies
according to perceptions, beliefs and attitudes about the
effectiveness and usefulness of OTC medication for treat-
ing symptoms, as well as potential side-effects (15). While
this varies at the individual level, previous research at the
population level has indicated that sales rates of OTC
medications (e.g. non-prescribed anti-diarrheal and anti-
nauseants) can reflect the occurrence of AGI at the
community-level in Canada (34). We found that the rates
of AGI-related OTC medication use were similar to
Ontario (35) but lower than British Columbia (4). Similar
to past studies (36), we found that missing paid employ-
ment due to AGI, severity of primary AGI symptoms,
secondary symptoms (e.g. headache, muscle pains, chills)
Fig. 4. Proportion of cases seeking healthcare for acute gastro-
intestinal illness (case definition: 3 or more loose stools/day and/
or vomiting in the past 28 days) for Netherlands (7), Rigolet,
Denmark (29), Quebec (22), Chile (26), Iqaluit, Cuba (28),
Argentina (21), Poland (23), Italy (6), China (24) and Malta (20).
Note: To compare results to international studies, Rigolet and
Iqaluit proportions are based on May survey data (28-day recall)
using a stricter case definition (September data are precluded).
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and younger ages were associated with increased odds of
OTC medication use.
Very few cases reported using traditional medicine to
treat AGI symptoms. Perhaps Inuit traditional remedies
are no longer regularly used for AGI in the 2 commu-
nities in this study; however, other research identified the
use of seal meat and oil (37) and medicinal plants (38) by
Baffin Island Inuit to treat AGI symptoms. One study
found that traditional Inuit medicine was reported to be
available by 11% of respondents in Nunatsiavut, and 16%
of respondents in Nunavut (39). Considering the higher
availability of traditional medicine in Nunavut (39), the
low use of Inuit traditional medicine to treat AGI symp-
toms in Iqaluit could reflect response bias or the more
‘‘urbanized’’ nature of Iqaluit compared to the other
much smaller communities in Nunavut.
For AGI to be captured by a surveillance system, the
case must come into contact with the healthcare system,
the healthcare provider must request a stool sample and
the case must comply with the request. Based on the low
number of cases seeking healthcare for AGI symptoms
and the infrequency of submitting stool samples for
Fig. 5. The under-reporting pyramids for acute gastrointestinal illness in Rigolet, Nunatsiavut, in September 2012 and May 2013, and
for Iqaluit, Nunavut, in September 2012 and May 2013.
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laboratory testing, our study suggests that AGI in Rigolet
and Iqaluit is likely substantially under-ascertained in
national surveillance records. But, of those who sought
medical care in Iqaluit, the proportion of cases from
whom stools samples were requested was 35% and 71%
of cases complied, which is higher than that reported
in other studies in Canada (4) and the USA (5). Unlike
other studies (4,40), we did not find any significant asso-
ciations between healthcare providers requesting stools
samples and secondary symptoms, age, or OTC medica-
tion use. When controlling for diarrheal symptoms, we
found increased odds of healthcare providers requesting
stool samples from Indigenous cases. However, there are
a number of demographic and clinical presentation consi-
derations that physicians take into consideration when
deciding whether or not to request a stool sample (4,41),
and our results are very exploratory in nature due to the
small sample size, and more research is warranted.
This study had several limitations. Firstly, this study
followed a cross-sectional design relying on self-reported
information with no pathogen testing, which could over-
or under-estimate AGI healthcare seeking behaviours
and OTC medication use due to recall bias. However,
we selected a 14-day recall period to minimize potential
recall bias based on local partner advice about reliably
recalling health care seeking behaviours. Furthermore,
the AGI case definition that was used is very sensitive
and captures symptoms caused by various conditions,
as well as infectious pathogens; as such, it is impossible
to determine how much of the burden was caused by
infection that could be captured by national surveillance
or other acute conditions that would not be captured by
national surveillance. Nonetheless, using this case defini-
tion facilitates comparison with data from Canada (4,10)
and also allows future re-analysis using more restrictive
definitions for international comparisons (6,20,21,23,24
26,28). Secondly, the p-values presented herein should
be considered exploratory in nature due to the small
sample size and power. Thirdly, data were captured at
2 points in time; while these results provide insights into
the fall and spring season in 2012 and 2013, the results
might not be representative of other seasons or times
of year and do not represent seasonal trends over time.
Furthermore, this study was conducted in 2 Inuit com-
munities to explore 2 different regions, a small and large
community, and an urban and rural setting; however,
caution should be used in generalizing the study results
given the variation and diversity among Inuit commu-
nities across the North. The response rates in Iqaluit
varied between September and May surveys; however, we
did not collect data on reasons why individuals declined
participation. We hypothesize that this difference in res-
ponse rates might be a result of better weather and
travel conditions in May, which might have impacted an
individual’s time available and motivation to participate
in the survey. Finally, while this study nearly achieved
Table V. Univariable exact logistic regression (for variables with pB0.20) and final multivariable logistic regression results, examining
the effects of predictor variables on the odds of visiting a health clinic or hospital for AGI in Iqaluit, Nunavut (September 2012 and
May 2013)
Iqaluit healthcare use (September and May)
Univariable logistic results Final multivariable logistic results
Predictor variable n Odds ratio p* 95% CI Odds ratio p* 95% CI
Variables in the final multivariable model
Missed traditional activities due to AGI No 95 ref.
Yes 28 4.591 0.003 1.47914.440 3.822 0.012 1.18012.463
Took OTC medication for AGI No 68 ref.
Yes 57 4.778 0.005 1.52218.001 3.882 0.018 1.17615.090
Variables considered in building the multivariable model
Vomited No 70 ref.   
Yes 55 4.055 0.0071 1.34813.870   
Food secure No 57 ref.   
Yes 68 0.360 0.041 0.1221.044   
Missed paid employment due to AGI No 71 ref.   
Yes 51 2.629 0.077 0.9128.050   
Household owns a vehicle No 47 ref.   
Yes 76 0.485 0.144 0.1661.396   
*Score method for estimating p-values does not assume a symmetrical distribution for discrete data. pB0.05 was considered significant.
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a census sample in Rigolet, the sample size was still small
and thus precluded multivariable modelling for this com-
munity. Still, the high response rate and similar demo-
graphics of the survey population and the Canadian
census for Rigolet is an important achievement and
presents a meaningful contribution to Indigenous health
literature.
Understanding what factors impact healthcare use
is important to inform and improve healthcare services,
and to increase the efficacy of public health surveillance.
While rates of self-reported AGI were higher in Inuit com-
munities compared to non-Inuit communities in Canada
(14), there were lower rates of AGI-related healthcare
use in Inuit communities compared to other regions in
Canada. Furthermore, the factors associated with health-
care use were different in Iqaluit than other studies in
Canada and USA (4,5). As such, the rates and predictors
of healthcare use for a given disease can differ between
Inuit and non-Inuit communities, and caution should be
exercised in making comparisons in health outcomes
between Inuit and non-Inuit communities based solely on
clinic records and healthcare use.
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